CEO Insights India

The diagnostic sector has witnessed major evolution during the last decade as cutting edge technology has given the scope of installing new processes for health checkups and covid related remedies. J-VPD Diagnostics India Pvt. Ltd. contributed exceptionally in this aspect by developing an integrated web and app based telemedicine solution. Led by Dinesh Chandra, the Director and CEO of the company, J-VPD Diagnostics experienced success of greater heights. He is a postgraduate in medical biotechnology and an organized, result oriented, problem solver professional with solid medical background. With about 15 years of experience in the Indian healthcare sector (IVD Industry) he is skilled in developing and implementing strategic plans as well as providing strong influence, prioritization, and project management.

In his latest interview with CEO Insights, Dinesh shares his views about the diagnostic industry and his role in steering J-VPD Diagnostics to success.

How would you define J-VPD Diagnostics as an organization and its position in the industry? What are the value additions offered by the company to its customers and what is its USP?
J-VPD Diagnostics is owned by J-VPD Inc situated in Tokyo, Japan. It stands for Japan’s Valuing Precision Diagnostics. We at J-VPD give special focus on diagnostic testing as we believe that it plays a vital role in preventive healthcare. We have been nurtured by Japanese healthcare for the last 30 years and hence we are striving to deliver Japanese medical products and technology across the globe without compromising precision and quality. We are working closely with Asia Pacific and Japan (APJ) Government Affairs to build strategies for India under the gui

dance of senior decision makers and key policy influencers within the Ministry for Health and Family Welfare, Ministry of Finance, NITI Aayog, Invest India and Indian Council of Medical Research (ICMR).

We are offering International Clinical Laboratory Testing Business along with state-of-the-art solutions in pharma ceutical, alternative medicine, tele medicine, histopathology, immune histochemistry, dialysis, oncology, allergy, immunotherapy, molecular genetics, cytogenetics, robotics, medical drone technology, and manufacturing under Govt ofIndia’s 'Make in India' initiative.

How has been your response to the challenges posted by the covid affected market and the need for new operational strategies?
COVID-19 has shaken the foundations of India’s healthcare system. Despite the initial hiccups, the healthcare system in India has managed to withstand the pandemic. The various efforts of manufacturing medical equipment, disposables, drugs and vaccination has helped India to shine in the global platform. India has not only fulfilled the domestic requirements, but also supported other countries. Digital adoption has taken a quantum leap at both the organizational and industry levels. During the pandemic, consumers have moved dramatically toward online channel which has resulted in bringing big success. Online consultations and technology platforms are thus in high demand today and J-VPD is transforming primary care by developing an integrated web and app-based telemedicine solution. It aims at making healthcare services fair by bridging the gap between urban and rural India.

What are the techniques or strategies you have acquired in your journey so far and how do you apply them in tackling complex situations in particular?

We display great vision to set the future of the organization, articulate mastery by inspiring motivating and communicating with clarity. We maintain integrity to retain a practical relationship and be consistently honest as well as being assertive to our customers to confidently and succinctly present a viewpoint. We also ensure that our actions match the words we speak and keep our thoughts balanced and truthful. We have less focus on the stress or and more on solving the problem.

Going forward, what are the changes in healthcare market that you anticipate and what are the opportunities that you foresee?
Covid-19 has transformed the way the government and private players are planning to bring change in the healthcare system. The biggest health emergencies of this times are not only the countless challenges and gaps in our healthcare sector but also the importance of investing in ‘well-being’ at both personal and system level. In this digitally and technically advanced era it is expected to help communities fulfil those requirements at a faster pace. Therefore, an increased focus on telemedicine services is noticed and the government has issued new guidelines to make telemedicine a legal practice in India. The Ministry of Health and Family Welfare (MoH&FW), along with NITI Aayog has rolled out the new guidelines that will allow registered medical practitioners (RMPs) to provide healthcare services using telemedicine.

Furthermore, the government has also launched the NDHM (National Digital health Mission) to address the country’s health crisis. The major components of this mission encompass telemedicine, health IDs, health records, along with e-pharmacy and Digi doctor services. India’s healthcare market is expected to reach $372 billion by 2022. The Indian government aims at increasing the healthcare spending to 2.5 percent of the GDP(gross domestic product) by 2025.

What advice would you give to the budding industry leaders of diagnostics healthcare domain?
I would tell them to be realistic by taking small steps towards improvement. They should keep working on difficult topics and remain positive by trying not to generalize criticisms.